Skip to Main Content

Paper Details

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
Nat Commun
119
2019
AR, BRCA2, BRCA2 aberrations, CDK12-/-, HRD, MSI, Metastatic castration-resistant prostate cancer, chromothripsis, genomic, homologous recombination deficiency, mCRPC, metastatic castration-resistant prostate cancers, microsatellite instability, non-coding regions, patients, tumor
BRCA2 Protein, Bone Neoplasms, Chromatin Immunoprecipitation Sequencing, Cyclin-Dependent Kinases, DNA Copy Number Variations, Enhancer Elements, Genetic, Genotype, Humans, Liver Neoplasms, Lymph Nodes, Male, Microsatellite Instability, Neoplasm Metastasis, Oncogene Proteins, Fusion, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Recombinational DNA Repair, Soft Tissue Neoplasms, Whole Genome Sequencing
Author NameAffiliation
Lisanne F van DesselErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Job van RietErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Job van RietErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Job van RietErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Minke SmitsRadboud University Nijmegen Medical Center
Yanyun ZhuThe Netherlands Cancer Institute
Yanyun ZhuOncode Institute
Paul Hamberg
Michiel S van der HeijdenCenter for Personalized Cancer Treatment
Michiel S van der HeijdenThe Netherlands Cancer Institute
Michiel S van der HeijdenThe Netherlands Cancer Institute
Andries M BergmanThe Netherlands Cancer Institute
Andries M BergmanThe Netherlands Cancer Institute
Inge M van OortRadboud University Nijmegen Medical Center
Ronald de WitErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Emile E VoestOncode Institute
Emile E VoestCenter for Personalized Cancer Treatment
Emile E VoestThe Netherlands Cancer Institute
Neeltje SteeghsCenter for Personalized Cancer Treatment
Neeltje SteeghsThe Netherlands Cancer Institute
Takafumi N YamaguchiOntario Institute for Cancer Research
Julie LivingstoneOntario Institute for Cancer Research
Paul C BoutrosOntario Institute for Cancer Research
Paul C BoutrosUniversity of Toronto
Paul C BoutrosUniversity of Toronto
Paul C BoutrosUniversity of California Los Angeles
Paul C BoutrosUniversity of California Los Angeles
Paul C BoutrosJonsson Comprehensive Cancer Centre, University of California Los Angeles
John W M MartensErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
John W M MartensCenter for Personalized Cancer Treatment
Stefan SleijferErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Stefan SleijferCenter for Personalized Cancer Treatment
Edwin CuppenCenter for Molecular Medicine and Oncode Institute, University Medical Center Utrecht
Edwin CuppenHartwig Medical Foundation
Wilbert ZwartThe Netherlands Cancer Institute
Wilbert ZwartOncode Institute
Wilbert ZwartLaboratory of Chemical Biology and Institute for Complex Molecular Systems, Eindhoven University of Technology
Harmen J G van de WerkenErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Harmen J G van de WerkenErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Niven MehraRadboud University Nijmegen Medical Center
Martijn P LolkemaErasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
Martijn P LolkemaCenter for Personalized Cancer Treatment
  • 1 - 42

Datasets